Top Story
Insurers, Payers Raise Price and Coverage Pressure on Pharma
Insurers, pharmacy benefit managers (PBMs), and public and private payers continue to challenge pharma prices, heightened by concerns about covering more new medicines to treat widespread conditions such as high cholesterol and diabetes. Jill Wechsler reports
...Read more
Roundtable
What’s Real in Rare Disease
Pharm Exec convened an expert panel on rare disease to highlight the challenges of serving expectant patients in this uniquely complex market access environment ...Read more
Europe
Edging Through Europe’s HTA Jungle
“Tell me what your drug is worth and I’ll tell you what you can charge” used to be to approach that pricing and reimbursement authorities took when a company came onto the market with a new medicine. Not any more. The rise of health technology assessment (HTA) has brought new layers and new players into the process, writes Reflector
...Read more
The UK Election’s Hot Healthcare Topics
Access to medicines — especially those for cancer — has remained a political hot topic in the UK and it's no surprise that it is a key issue as the countries' main political parties set out their stall in the run-up to the General Election on May 7. Leela Barham casts her eye over the parties' manifestoes to see what the future might hold
...Read more
Biosimilars
Biosimilars Ramp-Up: Five Themes for the Future
Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma. Casey McDonald reports
...Read more
|
